麻豆传媒

I am a Lecturer in Mitochondrial Therapeutics at the Translational and Clinical Research Institute at 麻豆传媒. My academic journey has been rooted here in 麻豆传媒, where I completed my BSc in Pharmacology in 2009 and my PhD in Mitochondrial Biology in 2014, before spending nearly a decade advancing my work as a Research Associate and Senior Research Associate.

Throughout my career I have sought to develop novel, high-throughput screening technologies to enable the identification of small molecule therapeutics. Initially this focused on the identification of therapies for mitochondrial disease, however these techniques have now been applied to rare neurological diseases and metabolic vulnerabilities in cancers. This work has been supported by international collaborations including Novartis, SME's and the Scripps Institute.

Area of expertise

Drug discovery

Mitochondrial biology

Quantification of mitochondrial function

High-throughput screening assay development

Qualifications

PhD 麻豆传媒

Mres 麻豆传媒 

BSc (Hons) Pharmacology, 麻豆传媒  

Google scholar: 

Research Interests



1. Identifying and developing novel therapeutics to improve mitochondrial function. Increasing mitochondrial function is key to improving the lives of patients with primary mitochondrial diseases, however this work also has broad applicability in neurological diseases where mitochondrial dysfunction is a secondary phenotype. This work is underpinned by the development of novel high-throughput screening technologies to identify small molecule mitochondrial activators. In collaboration with medicinal chemistry colleagues, this work is progressing towards pre-clinical in vivo investigations.
2. Development of screening techniques to identify therapeutic targets for rare diseases. Using advanced cell models (differentiated iPSC) and model cell lines (U2OS, HeLa, HEK293), we develop screenable assays to identify phenotypic changes in disease vs controls. Using CRISPR we identify genes that can correct disease phenotypes, thus identifying novel drug targets which we exploit with structural biology and medicinal chemistry colleagues.

NE-BRIDGE

NE-BRIDGE is a platform developed by myself and colleagues at 麻豆传媒 with local business partners to address key challenges and bottlenecks in the development of small molecule therapeutics for rare diseases. For more information please see: /who-we-are/strategy/strengths/ageing-health/rare-diseases/. Please contact me for more information or potential collaboration.

Undergraduate

Lecturer: CMB3011

Module Co-lead: BMD1004, BMD3017

Postgraduate

Lecturer: MMB5059

• Articles

  • Hipps D, Pyle A, Porter ALR, Dobson PF, Tuppen H, Lawless C, Russell OM, Turnbull DM, Deehan DJ, Hudson G. . Scientific Reports 2024, 14(1), 20989.
  • Franklin IG, Milne P, Childs J, Boggan RM, Barrow I, Lawless C, Gorman GS, Ng YS, Collin M, Russell OM, Pickett SJ. . Life Science Alliance 2023, 6(11), e202302271.
  • Di Leo V, Lawless C, Roussel MP, Gomes TB, Gorman GS, Russell OM, Tuppen HAL, Duchesne E, Vincent AE. . Journal of Neuromuscular Diseases 2023, 10(7), 1111-1126.
  • Lambourne OA, Bell S, Wilhelm LP, Yarbrough EB, Holly GG, Russell OM, Alghamdi AM, Fdel AM, Varricchio C, Lane EL, Ganley IG, Jones AT, Goldberg MS, Mehellou Y. . Journal of Medicinal Chemistry 2023, 66(11), 7645-7656.
  • Chen C, McDonald D, Blain A, Mossman E, Atkin K, Marusich MF, Capaldi R, Bone L, Smith A, Filby A, Erskine D, Russell O, Hudson G, Vincent AE, Reeve AK. . npj Parkinson's Disease 2023, 9, 120.
  • Nolden KA, Egner JM, Collier JJ, Russell OM, Alston CL, Harwig MC, Widlansky ME, Sasorith S, Barbosa IA, Douglas AG, Baptista J, Walker M, Donnelly DE, Morris AA, Tan HJ, Kurian MA, Gorman K, Mordekar S, Deshpande C, Samanta R, McFarland R, Hill RB, Taylor RW, Olahova M. . Life Science Alliance 2022, 5(12), e202101284.
  • Hipps D, Dobson PF, Warren C, McDonald D, Fuller A, Filby A, Bulmer D, Laude A, Russell O, Deehan DJ, Turnbull DM, Lawless C. . Bone 2022, 158, 116371.
  • Smith ALM, Whitehall JC, Bradshaw C, Gay D, Robertson F, Blain AP, Hudson G, Pyle A, Houghton D, Hunt M, Sampson JN, Stamp C, Mallett G, Amarnath S, Leslie J, Oakley F, Wilson L, Baker A, Russell OM, Johnson R, Richardson CA, Gupta B, McCallum I, McDonald SAC, Kelly S, Mathers JC, Heer R, Taylor RW, Perkins ND, Turnbull DM, Sansom OJ, Greaves LC. . Nature Cancer 2020, 1, 976-989.
  • Russell OM, Fruh I, Rai PK, Marcellin D, Doll T, Reeve A, Germain M, Bastien J, Rygiel KA, Cerino R, Sailer AW, Lako M, Taylor RW, Mueller M, Lightowlers RN, Turnbull DM, Helliwell SB. . Scientific Reports 2018, 8(1), 1799.
  • Rai PK, Russell OM, Lightowlers RN, Turnbull DM. . British Medical Bulletin 2015, 116(1), 5-18.

• Editorial

  • Russell OM, Lightowlers RN, Turnbull DM. . Molecular Cell 2016, 62(1), 5-6.

• Note

  • Lightowlers RN, Chrzanowska-Lightowlers ZMA, Russell OM. . EMBO Reports 2020, 21(9), e50964.

• Reviews

  • Russell OM, Gorman GS, Lightowlers RN, Turnbull DM. . Cell 2020, 181(1), 168-188.
  • Ahmed ST, Craven C, Russell OM, Turnbull DM, Vincent AE. . Neurotherapeutics 2018, 15(4), 943-953.
  • Rai PK, Craven L, Hoogewijs K, Russell OM, Lightowlers RN. . Essays in Biochemistry 2018, 62(3), 455-465.
  • Russell O, Turnbull D. . Experimental Cell Research 2014, 325(1), 38-43.